Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 1Leukemia, Myelomonocytic, Chronic 1COVID-19 1

Interventions

fludarabine phosphate 52Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 42Busulfan 37Azacitidine 34Whole-Body Irradiation 31Mycophenolic Acid 29Cytarabine 28Cyclosporine 28Tacrolimus 27Methotrexate 25Filgrastim 21Decitabine 20Radiotherapy 19Antilymphocyte Serum 19Methylprednisolone 14Melphalan 13Etoposide 13fludarabine 10Cyclosporins 9Idarubicin 8Granulocyte Colony-Stimulating Factor 8Flow Cytometry 8sargramostim 7Psychiatric Rehabilitation 7Cord Blood Stem Cell Transplantation 7merphos 6aldesleukin 6Topotecan 6Therapeutics 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelomonocytic, Chronic × lenzilumab × Clear all
NCT02546284 2020-02-28

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

Humanigen, Inc.

Phase 1 Completed
15 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡